NASDAQ:EYEG - Eyegate Pharmaceuticals Stock Price, Forecast & News

Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."

Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) announced its quarterly earnings data on Thursday, November, 7th. The specialty pharmaceutical company reported ($1.15) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.75) by $0.40. View Eyegate Pharmaceuticals' Earnings History.

Eyegate Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, March 6th 2020. View Earnings Estimates for Eyegate Pharmaceuticals.

Media stories about EYEG stock have trended positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Eyegate Pharmaceuticals earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Eyegate Pharmaceuticals.

Eyegate Pharmaceuticals saw a decline in short interest in the month of December. As of December 13th, there was short interest totalling 106,400 shares, a decline of 57.9% from the November 28th total of 252,600 shares. Based on an average daily volume of 310,500 shares, the short-interest ratio is presently 0.3 days. Approximately 3.3% of the company's shares are short sold. View Eyegate Pharmaceuticals' Current Options Chain.

Some companies that are related to Eyegate Pharmaceuticals include Aptinyx (APTX), vTv Therapeutics (VTVT), OASMIA PHARMACE/ADR (OASM), Gemphire Therapeutics (GEMP), NeuBase Therapeutics (NBSE), CELYAD SA/ADR (CYAD), Millendo Therapeutics (MLND), Clearside Biomedical (CLSD), Otonomy (OTIC), CV Sciences (CVSI), Aduro BioTech (ADRO), Stealth BioTherapeutics (MITO), Axovant Gene Therapies (AXGT), AVEO Pharmaceuticals (AVEO) and Bellicum Pharmaceuticals (BLCM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Eyegate Pharmaceuticals investors own include Bausch Health Companies (BHC), MannKind (MNKD), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Canopy Growth (CGC), Arca Biopharma (ABIO) and Anavex Life Sciences (AVXL).

(EYEG) raised $5 million in an initial public offering on Friday, February 13th 2015. The company issued 800,000 shares at a price of $6.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO.

Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EYEG stock can currently be purchased for approximately $6.85.

Eyegate Pharmaceuticals has a market capitalization of $27.74 million and generates $1.65 million in revenue each year. The specialty pharmaceutical company earns $-10,810,000.00 in net income (profit) each year or ($4.50) on an earnings per share basis. Eyegate Pharmaceuticals employs 11 workers across the globe.View Additional Information About Eyegate Pharmaceuticals.

The official website for Eyegate Pharmaceuticals is http://www.eyegatepharma.com/.

Eyegate Pharmaceuticals' mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at 781-788-8869.